Why we chose pluripotent exosomes and VEGF-A over fillers and Botox

At Blast Institute, we hold a simple conviction that shapes everything we do — the body already knows how to heal itself. It has done so for as long as you have been alive. What it loses with time is not the knowledge, but the signal: the clear instruction and the steady supply of resources that keep repair humming along. Our work is to restore that conversation.

Nowhere is this philosophy more visible — literally — than on the skin of your face and scalp. So when clients ask us why our aesthetic approach looks so different from the menu at a typical medical spa, the honest answer is that we set out to solve a different problem. Most aesthetic medicine asks: how do we cover the signs of aging? We ask: how do we help the tissue become young again?

The problem with filling and freezing

Dermal fillers and neurotoxins like Botox are the two pillars of conventional cosmetic practice, and we understand their appeal — the results are fast and visible. But look closely at what they actually do.

Fillers add volume by introducing a foreign material beneath the skin. They occupy space; they do not rebuild the tissue that was lost. Over time, they migrate, they must be redone, and in some cases they interfere with the skin’s own architecture. Neurotoxins work by paralyzing the small muscles that create expression lines. The wrinkle softens because the muscle can no longer move — not because the skin has been restored.

Both approaches share the same underlying logic: they mask the appearance of aging rather than address its biology. That logic is precisely what we chose to leave behind. At Blast, we have resolutely removed fillers and neurotoxins from our aesthetic practice. Not because they never work, but because we believe our clients deserve an approach that works with their biology rather than around it.

Our approach: stimulus, instruction, and supply

Regenerating skin — whether on the face, the body, or the scalp — comes down to three things working together. Think of it as waking the tissue up, telling it what to do, and making sure it has the fuel to do it.

1. The stimulus — Plasmage, Jovena, and microneedling. Before the skin will rebuild, it needs a reason to — and we give it one without destroying tissue. Plasmage (a precision plasma device) and Jovena (which pairs plasma with radiofrequency energy) deliver controlled, non-ablative stimulation that prompts the skin’s own fibroblasts — the cells responsible for producing collagen and elastin — to begin remodeling. Microneedling adds a mechanical version of the same invitation, and does something else just as valuable: it opens temporary micro-channels in the skin, creating a direct pathway for what comes next. None of these tools remove or freeze anything. They simply signal the tissue to renew itself — which is exactly why they belong in a regenerative practice.
2. The instruction — pluripotent stem cell-derived exosomes. This is the heart of what makes Blast different. Exosomes are tiny vesicles that cells use to talk to one another — nature’s own messaging system, carrying growth factors and regulatory signals from one cell to the next. The critical distinction, and one we insist on, is the source of those exosomes.

Many clinics use exosomes derived from mesenchymal stem cells (MSCs). Our exosomes are derived from pluripotent stem cells (PSCs) — the most primal, unspecialized cells in biology, from which every tissue type originates. Their signaling profile reflects that developmental potency. When delivered through the micro-channels created by microneedling, these pluripotent exosomes carry a richer, more youthful set of repair instructions directly to the cells that need them. They do not become your skin; they tell your skin how to renew itself.

3. The supply — VEGF-A gene therapy. Even the best instructions fail if the tissue is starved. As skin and scalp age, one of the quiet losses is perfusion — the network of tiny blood vessels that deliver oxygen and nutrients. VEGF-A (Vascular Endothelial Growth Factor A) is the body’s own signal for building new microvasculature. Our VEGF-A gene therapy places this instruction precisely where it is needed, prompting the local tissue to restore its own blood supply.

An important point of honesty and precision here: VEGF-A gene therapy acts locally. Its effect is concentrated right at the site where it is administered and fades within centimeters — it is never systemic. That is not a limitation; for facial skin and scalp, it is exactly what you want. A targeted, localized boost in perfusion, delivered to the area being treated, feeding the very cells the exosomes have just instructed.

Together, these three create a closed loop of renewal: the stimulus wakes the tissue, the exosomes instruct it, and VEGF-A sustains the supply line that lets the repair actually happen.

Why this matters for the scalp — for everyone

Hair thinning is often framed as a men’s concern, but that picture is incomplete and it leaves a great many people underserved. Female pattern hair loss affects roughly one in three women over the course of a lifetime, and the conventional pharmaceutical mainstay — finasteride — is contraindicated for women of childbearing age. That leaves a large population with few good options.

To understand why our approach works here, it helps to understand why hair thins in the first place. In much of hair loss — central to male pattern balding, and a contributor for many women as well — the problem is the follicle’s sensitivity to DHT (dihydrotestosterone). DHT does not simply “clog” a follicle. It switches the follicle toward a shutdown program: by binding androgen receptors in the dermal papilla, it raises inhibitory signals such as TGF-β1 and quiets the Wnt/β-catenin pathway that keeps hair in its active growth phase.1,2 The follicle gradually miniaturizes. This is the key insight behind our combination — a follicle still receiving that “stop” signal cannot fully use the extra blood supply that VEGF-A provides.

This is where the exosomes matter most. Their role is not to remove DHT, but to work downstream of it — delivering regenerative signals that help quiet the inhibitory pathway4 and reawaken the follicle’s own growth program.3,5,6 In effect, the exosomes help release the brake, while localized VEGF-A restores the fuel line. Signal and supply, working together on the same follicle.

And because this strategy is non-hormonal, it is as appropriate for women as it is for men — a meaningful advantage given how few good options exist for female hair thinning.

What to expect

Regeneration is a process, not a single dramatic reveal. Because we are prompting your own tissue to rebuild, results develop gradually and continue to improve in the weeks following treatment as new collagen forms and perfusion is restored. What our clients notice is not a “frozen” or filled look, but skin that simply looks and behaves healthier — more resilient, better toned, more alive. Because the improvement is your own tissue, it is genuinely yours.

Every person’s biology is different, and outcomes vary from individual to individual. During your consultation we design a protocol suited to your skin, your goals, and your history.

The Blast difference

The choice between masking and repairing is, at bottom, a philosophical one — and we made ours deliberately. We would rather give your body the stimulus, the instruction, and the supply it needs to become genuinely younger than paint over the surface of time. It is a slower promise, and a truer one.

If you would like to understand how this approach might work for your skin or scalp, we would be glad to talk with you.

References

1. Chew EGY, et al. The AR/miR-221/IGF-1 pathway mediates the pathogenesis of androgenetic alopecia. International Journal of Molecular Sciences (PMC10367565), 2023.
2. Sharma AR, et al. Perspectives on miRNAs Targeting DKK1 for Developing Hair Regeneration Therapy. Cells (MDPI 10:2957), 2021.
3. Liang Y, et al. Human umbilical cord mesenchymal stem cell-derived exosomes enhance follicular regeneration in androgenetic alopecia via activation of the Wnt/β-catenin pathway. Stem Cell Research & Therapy (PMC12317459), 2025.
4. Liang Y, et al. Adipose mesenchymal stromal cell-derived exosomes carrying miR-122-5p antagonize the inhibitory effect of dihydrotestosterone on hair follicles by targeting the TGF-β1/SMAD3 signaling pathway. International Journal of Molecular Sciences (PMC10059832), 2023.
5. Adipose-derived stem cell exosomes antagonize the inhibitory effect of dihydrotestosterone on hair follicle growth by activating the Wnt/β-catenin pathway. PMC10551537, 2023.
6. Fu Y, et al. Mesenchymal stem cell exosomes enhance the development of hair follicle to ameliorate androgenetic alopecia. World Journal of Stem Cells (PMID 40160691), 2025.

This article is for educational purposes and describes the philosophy and modalities offered at Blast Institute. It is not medical advice, and it does not guarantee specific outcomes. A personal consultation is the right place to determine what is appropriate for you.